October 11, 2022 08:35 AM EDTUpdated 09:15 AM
R&D
Pharma
Coronavirus

No speedy nasal roll­out for Ox­ford/As­traZeneca’s Covid-19 jab af­ter PhI flop

Kyle LaHucik

Senior Reporter

Ox­ford/As­traZeneca’s nasal spray vac­cine per­formed poor­ly in an ear­ly-stage study, squash­ing hopes for a quick ad­vance­ment of the duo’s orig­i­nal for­mu­la­tion via an in­oc­u­la­tion at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times